


Listing of claims

Claims 1-45 (canceled)

46. (currently amended) The (R) isomer of a compound according to formula I wherein:



Formula I

 R^1 is (C_{1-6}) alkyl; R^2 is halogen or $-OR'$; R^3 is hydrogen or $-OR'$; R' is hydrogen, (C_{1-6}) alkyl, or SO_2R'' ; R'' is (C_{1-6}) alkyl, haloalkyl,

aryl or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with a group selected from (C_{1-6}) alkyl, halo, haloalkyl, cyano, nitro, alkylsulfonyl, and alkylsulfonylamino;

R^4 is (i) (C_{1-6}) alkyl, (ii) aryl, heterocyclyl, or heteroaryl, wherein said aryl, heterocyclyl or heteroaryl groups are optionally substituted with a group selected from (C_{1-6}) alkyl, halo, haloalkyl, (C_{1-6}) alkoxy, cyano, amino, mono- or di alkylamino, nitro, alkylsulfonyl, alkylcarbonyl, urca, alkylcarbonylamino, alkylsulfonylamino, alkylaminosulfonyl, alkoxy carbonyl, heterocyclyl and heteroaryl, or (iii) $-NR^5R^6$; and

R^5 and R^6 are independently of each other hydrogen, (C_{1-6}) alkyl, aryl or heterocyclyl; wherein said aryl or heterocyclyl groups are optionally substituted with (C_{1-6}) alkyl, halo, haloalkyl, cyano, (C_{1-6}) alkoxy, and alkylsulfonyl;

or an individual isomer, a racemic or non-racemic mixture of isomers; or an acceptable salt or solvate thereof; with the proviso that the compound is other than {4-[(R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperidin-4-yl-methanone.

47. (previously added) The compound of Claim 46, wherein R^2 is (C_{1-6}) alkoxy and R^3 is hydrogen.48. (previously added) The compound of Claim 46, wherein R^2 is (C_{1-6}) alkoxy and R^3 is (C_{1-6}) alkoxy.

49. (previously added) The compound of Claim 46, wherein R² is -OSO₂R" and R³ is hydrogen.

50. (previously addcd) The compound of Claim 46, wherein R² is hydroxy and R³ is hydrogen.

51. (previously added) The compound of Claim 46, wherein R² is halogen and R³ is hydrogen.

52. (previously added) The compound of Claim 46 wherein R⁴ is (C₁₋₆)alkyl.

53. (previously added) The compound of Claim 52, wherein R¹ is ethyl or propyl.

54. (previously added) The compound of Claim 53, wherein R² is -OR¹, and R³ is -OR¹ or hydrogen.

55. (previously added) The compound of Claim 46, wherein R⁴ is an aryl group.

56. (previously added) The compound of Claim 55, wherein R⁴ is phenyl optionally substituted with a group selected from (C₁₋₆)alkyl, halo, haloalkyl, (C₁₋₆)alkoxy, cyano, amino, mono- or di alkylamino, nitro, alkylsulfonyl, alkylcarbonyl, urea, alkylcarbonylamino, alkylsulfonylamino, alkylaminosulfonyl, alkoxycarbonyl, heterocyclyl and heteroaryl.

57. (previously added) The compound of Claim 55, wherein R¹ is ethyl or propyl.

58. (previously added) The compound of Claim 56, wherein R¹ is ethyl or propyl.

59. (previously added) The compound of Claim 58, wherein R² is -OR¹, and R³ is -OR¹ or hydrogen.

60. (previously added) The compound of Claim 46, wherein R⁴ is a heteroaryl group.

61. (previously added) The compound of Claim 60, wherein R⁴ is selected from furanyl, thiophenyl, isooxazolyl, oxazolyl, imidazolyl, and pyrazolyl, all optionally substituted with one or two (C₁₋₆) alkyl.

62. (previously added) The compound of Claim 60, wherein R¹ is ethyl or propyl.

63. (previously added) The compound of Claim 61, whercin R¹ is ethyl or propyl.

64. (previously added) The compound of Claim 63, wherein R² is -OR¹, and R³ is -OR¹ or hydrogen.

65. (previously added) The compound of Claim 46, wherein R⁴ is a heterocyclyl group.

66. (previously added) The compound of Claim 65, wherein R⁴ is piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, or diazepanyl, all optionally substituted with one or two (C₁₋₆)alkyl or alkylcarbonyl groups.

67. (previously added) The compound of Claim 65, wherein R⁴ is piperidin-4-yl, optionally substituted with one or two (C₁₋₆)alkyl groups or alkylcarbonyl groups.

68. (previously added) The compound of Claim 65, wherein R⁴ is piperidin-1-yl, optionally substituted with one or two (C₁₋₆)alkyl groups.

69. (previously added) The compound of Claim 65, wherein R⁴ is pyrrolidin-1-yl, optionally substituted with one or two (C₁₋₆)alkyl groups.

70. (previously added) The compound of Claim 65 wherein R⁴ is [1,4]-diazepany-1-yl, optionally substituted with one or two (C₁₋₆)alkyl groups.

71. (previously added) The compound of Claim 65, wherein R⁴ is piperazin-1-yl, optionally substituted with one or two (C₁₋₆)alkyl groups.

72. (previously added) The compound of Claim 65, wherein R⁴ is morpholinyl, optionally substituted with one or two (C₁₋₆)alkyl groups.

73. (previously added) The compound of Claim 65, wherein R¹ is ethyl or propyl.

74. (previously added) The compound of Claim 66, wherein R¹ is ethyl or propyl.

75. (previously added) The compound of Claim 74, wherein R² is -OR¹, and R³ is -OR¹ or hydrogen.

76. (previously added) The compound of Claim 46, wherein R⁴ is -NR⁵R⁶.

U.S. Serial No. 10/608,604

Atty Docket No.-R0125C-CON

77. (previously added) The compound of Claim 76, wherein R⁵ is (C₁₋₆)alkyl, and R⁶ is hydrogen or (C₁₋₆)alkyl.

78. (previously added) The compound of Claim 76, wherein R¹ is ethyl or propyl.

79. (previously added) The compound of Claim 78, wherein R² is -OR', and R³ is -OR' or hydrogen.

80. (previously added) The compound of Claim 46, comprising:

{4-[(*(R)*-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-methanone;

{4-[(*(R)*-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-morpholin-4-yl-methanone;

{4-[(*(R)*-6,7-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperidin-4-yl-methanone;

1-{4-[(*(R)*-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-ethanone;

{4-[(*(R)*-6,7-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperazin-1-yl-methanone;

{4-[(*(R)*-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-(4-methyl-piperazin-1-yl)-methanone; and

{4-[(*(R)*-7-Bromo-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperidin-4-yl-methanone.

81. (previously added) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 46 in admixture with an acceptable carrier.

82. (previously added) The pharmaceutical composition of Claim 81, wherein the compound is suitable for administration to a subject having a disease state which is alleviated by treatment with a M2/M3 muscarinic receptor antagonist.

83. (previously added) A method of treating a subject which comprises administering to the subject with a disease treatable with a M2/M3 muscarinic antagonist a therapeutically effective amount of one or more compounds of Claim 46.

84. (previously added) The method of Claim 83, wherein the disease state is associated with smooth muscle disorders comprising diseases of the genitourinary or gastrointestinal tract, or of respiratory states.

85. (previously added) The method of Claim 84, wherein the disease state is associated with the genitourinary tract.


86. (previously added) The method of Claim 85, wherein the disease state comprises overactive bladder, detrusor hyperactivity, urgency, frequency, reduced bladder capacity, incontinence episodes, changes in bladder capacity, micturition threshold, unstable bladder contractions, sphincteric spasticity, outlet obstruction, outlet insufficiency, pelvic hypersensitivity, idiopathy conditions, or detrusor instability.

87. (previously added) The method of treatment of Claim 84, wherein the disease state comprises respiratory states.

88. (previously added) The method of treatment of Claim 87, wherein the disease state comprises respiratory states from allergies or asthma.


89. (previously added) The method of treatment of Claim 84, wherein the disease state comprises gastrointestinal tract disorders.

90. (previously added) A process for preparing a compound as claimed in Claim 46 which process comprises reacting a compound having a general formula d:



wherein R¹, R² and R³ are as described in Claim 46,

with a compound of general Formula R⁴C(O)L, wherein L is a leaving group and R⁴ is as described in Claim 46, to prepare a compound of Formula I



wherein R¹, R², R³ and R⁴ are as described in Claim 46.